Photys bringing PROTAC logic to phosphorylation with $75M series A

Photys is the latest newco to apply the targeting chimera structure popularized by PROTACs to another form of protein modification, and the first to take aim at phosphorylation.

Boston-based Photys Therapeutics Inc., founded by phosphorylation-inducing chimeric small molecule (PHIC) pioneer Amit Choudhary and Longwood Fund, emerged from stealth Thursday with a $75 million series A round led by MPM Capital. ...